1. Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat. Med. 1995; 1: 658-660. doi: 10.1038/nm0795-658
2. Akerman S, Holland PR, Goadsby PJ. Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci. 2011; 12: 570-584. doi: 10.1038/nrn3057
3. Cohen AS, Goadsby PJ. Functional neuroimaging of primary headache disorders. Expert Rev. Neurother. 2006; 6: 1159-1171. doi: 10.1586/14737175.6.8.1159
4. Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine-revised report of an EFNS task force. Eur J Neurol. 2009; 16: 968-981.doi: 10.1111/j.1468-1331.2009.02748.x
5. Samsam M, Coveñas R, Ahangari R, Yajeya J, Narváez JA, Tramu G. Simultaneous depletion of neurokinin A, substance P and calcitonin gene related peptide immunoreactivities in the caudal trigeminal nucleus of the rat following electrical stimulation of the Gasserian ganglion: a possible co-release of neuropeptides. PAIN. 2000; 84: 389-395. doi: 10.1016/s0304-3959(99)00240-7
6. Friberg L, Olesen J, Olsen TS, Karle A, Ekman R, Fahrenkrug J. Absence of vasoactive peptide release from brain to cerebral circulation during onset of migraine with aura. Cephalalgia. 1994; 14(1): 47-54. doi: 10.1046/j.1468-2982.1994.1401047.x
7. Gallai V, Sarchielli P, Floridi A, et al. Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia. 1995; 15(5): 384-390. doi: 10.1046/j.1468-2982.1995.1505384.x
8. Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia.2002; 22(1): 54-61. doi: 10.1046/j.1468-2982.2002.00310.x
9. Villalón CM, Olesen J. The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. Pharmacol Ther. 2009; 124: 309-323. doi: 10.1016/j.pharmthera.2009.09.003
10. Karsan N, Goadsby PJ. CGRP mechanism antagonists and migraine management. Curr Neurol Neurosci Rep. 2015; 15(5): 25. doi: 10.1007/s11910-015-0547-z
11. Edvinsson L. CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment. Br J Clin Pharmacol. 2015; 80(2): 193-199. doi: 10.1111/bcp.12618
12. Bigal ME, Walter S, Rapoport AM. Therapeutic antibodies against CGRP or its receptor. Br J Clin Pharmacol. 2015; 79(6): 886-895. doi: 10.1111/bcp.12591
13. Tfelt-Hansen P, Olesen J. Possible site of action of CGRP antagonists in migraine. Cephalalgia. 2011; 31: 748-750. doi: 10.1177/0333102411398403
14. Humphrey PP. The discovery and development of the triptans, a major therapeutic breakthrough. Headache. 2008; 48: 685-687. doi: 10.1111/j.1526-4610.2008.01097.x
15. Olesen J, Diener HC, Husstedt IW, et al. BIBN 4096 BS clinical proof of concept study group. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004; 350(11): 1104-1110. doi: 10.1056/NEJMoa030505
16. Ho TW, Mannix LK, Fan X, et al. MK-0974 protocol 004 study group. Collaborators (20), randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology. 2008; 70: 1304-1312. doi: 10.1212/01.wnl.0000286940.29755.61
17. Connor K.M, Shapiro RE, Diener HC, et al. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology. 2009; 73: 970-977. doi: 10.1212/WNL.0b013e3181b87942
18. Iovino M, Feifel U, Yong CL, Wolters JM, Wallenstein G. Safety, tolerability and pharmacokinetics of BIBN 4096 BS, the first selective small molecule calcitonin gene-related peptide receptor antagonist, following single intravenous administration in healthy volunteers. Cephalalgia. 2004; 24: 645-656. doi: 10.1111/j.1468-2982.2004.00726.x
19. Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008; 372: 2115-2123. doi: 10.1016/S0140-6736(08)61626-8
20. Samsam M, Coveñas R, Ahangari R, Yajeya J. Neuropeptides and other chemical mediators, and the role of anti-inflammatory drugs in primary headaches. AIAA-MC. 2010; 3: 170-188. doi: 10.2174/1871523011009030170
21. Diener HC, Barbanti P, Dahlöf C, Reuter U, Habeck J, Podhorna J. BI44370TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia. 2011; 31(5): 573-584. doi: 10.1177/0333102410388435
22. Salvatore CA, Moore EL, Calamari A, et al. Pharmacological properties of MK-3207, a potent and orally active calcitonin gene-related peptide receptor antagonist. J Pharmacol Exp Ther. 2010; 333: 152-160. doi: 10.1124/jpet.109.163816
23. Hewitt DJ, Aurora SK, Dodick DW, et al. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia. 2011; 31: 712-722. doi: 10.1177/0333102411398399
24. Leahy DK, Fan Y, Desai LV, et al. Efficient and scalable enantioselective synthesis of a CGRP antagonist. Org Lett. 2012; 14: 4938-4941. doi: 10.1021/ol302262q
25. Luo G, Chen L, Conway CM, et al. Discovery of BMS-846372, a potent and orally active human CGRP receptor antagonist for the treatment of migraine. ACS Med Chem Lett. 2012; 3: 337-341. doi: 10.1021/ml300021s
26. Merck Sharp & Dohme Corp. A pharmacokinetic study of MK-1602 in the treatment of acute migraine (MK-1602-007). Website: https://clinicaltrials.gov/ct2/show/NCT01657370 2012; Accessed January 2015.
27. Durham PL, Vause CV. Calcitonin gene-related peptide (CGRP) receptor antagonists in the treatment of migraine. CNS Drugs. 2010; 24: 539-548. doi: 10.2165/11534920-000000000-00000
28. Poyner DR, Sexton PM, Marshall I, et al. Foord SM. International union of pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev. 2002; 54: 233-246. doi: 10.1124/pr.54.2.233
29. Bigal ME, Walter S. Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity. CNS Drugs. 2014; 28(5): 389-399. doi: 10.1007/s40263-014-0156-4
30. Reuter U. Anti-CGRP antibodies: a new approach to migraine prevention. Lancet Neurol. 2014; 13(9): 857-859. doi: 10.1016/S1474-4422(14)70126-7
31. Samsam M. Drugs against calcitonin gene-related peptide and its receptor used in the treatment of migraine: what are the new progresses? Neuro Open J. 2015; 2: 79-91. doi: 10.17140/NOJ-2-117
32. Eli Lilly and Company. CGRP mAb migraine prevention Website: http://www.lilly.com/SiteCollectionDocuments/Pipeline/Clinical%20Development%20Pipeline/10.html 2015; Accessed August, 2015.
33. Alder Biopharmaceuticals Inc. A parallel group, double-blind, randomized, placebo controlled dose-ranging phase 2 trial to evaluate the efficacy, safety, and pharmacokinetics of ALD403 administered intravenously in patients with chronic migraine. Website: http://www.alderbio.com/clinical-trials/ 2015; Accessed August, 2015.
34. Teva Pharmaceuticals. Teva to present new findings at the American Headache Society (AHS) Meeting-analysis of migraine phase IIb studies provides novel insights into TEV-48125 efficacy and safety in both episodic & chronic migraine. Website: http://news.tevausa.com/mobile.view?c=251945&v=203&d=1&id=2060482 2015; Accessed August, 2015.
35. Amgen. Amgen to present AMG 334 data at 17th congress of the international headache society: data evaluating safety and efficacy of AMG 334 provides new insights into preventive treatment of migraine. Website: http://wwwext.amgen.com/media/media_pr_detail.jsp?year=2015&releaseID=2046668 2015; Accessed August, 2015.
36. Dodick DW, Goadsby PJ, Spierings EL, Scherer JC, Sweeney SP, Grayzel DS. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2014; 13(9): 885-892. doi: 10.1016/S1474-4422(14)70128-0
37. Dodick DW, Goadsby PJ, Silberstein SD, et al. ALD403 study investigators. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. 2014; 13(11): 1100-1107. doi: 10.1016/S1474-4422(14)70209-1
38. Bigal ME, Escandon R, Bronson M, et al. Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: results of the phase 1 program. Cephalalgia. 2013; 34(7): 483-492. doi: 10.1177/0333102413517775
39. PRNewswire/THOUSAND OAKS, Calif. Amgen presents open-label extension data from ongoing phase 2 study of AMG 334 in the prevention of episodic migraine: http://wwwext.amgen.com/media/media_pr_detail.jsp?year=2015&releaseID=2061044 2015; Accessed June 19, 2015.
40. Szallasi A, Blumberg PM. Vanilloid (Capsaicin) receptors and mechanisms. Pharmacol Rev. 1999; 51: 159-212.
41. Nakanishi M, Hata K, Nagayama T, et al. Acid activation of Trpv1 leads to an up-regulation of calcitonin gene-related peptide expression in dorsal root ganglion neurons via the CaMK-CREB cascade: a potential mechanism of inflammatory pain. Mol Biol Cell. 2010; 21(15): 2568-2577. doi: 10.1091/mbc.E10-01-0049
42. Szallasi A, Sheta M. Targeting TRPV1 for pain relief: limits, losers and laurels. Expert Opin Investig Drugs. 2012; 21: 1351-1369. doi: 10.1517/13543784.2012.704021
43. Kaneko Y, Szallasi A. Transient receptor potential (TRP) channels: a clinical perspective. Br J Pharmacol. 2014; 171: 2474-2507. doi: 10.1111/bph.12414
44. Riera CE, Huising MO, Follett P, et al. TRPV1 pain receptors regulate longevity and metabolism by neuropeptide signaling. Cell. 2014; 157(5): 1023-1036. doi: 10.1016/j.cell.2014.03.051
45. Hoffmann J, Goadsby PJ. Emerging targets in migraine. CNS Drugs. 2014; 28: 11-17. doi: 10.1007/s40263-013-0126-2
46. Diener HC, Charles A, Goadsby PJ, et al. New therapeutic approaches for the prevention and treatment of migraine. Lancet Neurol. 2015; 14: 1010-1022. doi: 10.1016/S1474-4422(15)00198-2